Imatinib Mesylate Exerts Anti-Proliferative Effects on Osteosarcoma Cells and Inhibits the Tumour Growth in Immunocompetent Murine Models
暂无分享,去创建一个
Frederic Blanchard | G. Moriceau | D. Heymann | Bérengère Gobin | Gatien Moriceau | Benjamin Ory | Céline Charrier | Régis Brion | Françoise Redini | Dominique Heymann | B. Ory | F. Blanchard | F. Redini | R. Brion | C. Charrier | B. Gobin
[1] K. Antman,et al. Imatinib mesylate--a new oral targeted therapy. , 2002, The New England journal of medicine.
[2] L. Shultz,et al. Establishment and characterization of a new osteogenic cell line (MOS-J) from a spontaneous C57BL/6J mouse osteosarcoma. , 2002, In vivo.
[3] P. Lollini,et al. NVP-BEZ235 as a New Therapeutic Option for Sarcomas , 2010, Clinical Cancer Research.
[4] Randall T. Moon,et al. Proximal events in Wnt signal transduction , 2009, Nature Reviews Molecular Cell Biology.
[5] L. Jia,et al. Knockdown of AXL Receptor Tyrosine Kinase in Osteosarcoma Cells Leads to Decreased Proliferation and Increased Apoptosis , 2013, International journal of immunopathology and pharmacology.
[6] Tomoyuki Saito,et al. Inhibition of lung metastasis of osteosarcoma cell line POS-1 transplanted into mice by thigh ligation. , 2002, Cancer letters.
[7] J. Blay,et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] G. Rosen,et al. Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma , 1976, Cancer.
[9] Gerhard Dürnberger,et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. , 2007, Blood.
[10] Dong Ho Kim,et al. Epidermal Growth Factor Receptor: Is It a Feasible Target for the Treatment of Osteosarcoma? , 2012, Cancer research and treatment : official journal of Korean Cancer Association.
[11] C. Antonescu,et al. Platelet‐derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma , 2008, Cancer.
[12] P. Layrolle,et al. Adhesion and osteogenic differentiation of human mesenchymal stem cells on titanium nanopores. , 2011, European cells & materials.
[13] Anne-Marie Cleton-Jansen,et al. IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma , 2013, BMC Cancer.
[14] E. Kleinerman,et al. Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines , 2012, Oncogenesis.
[15] Daisuke Kitagawa,et al. Activity‐based kinase profiling of approved tyrosine kinase inhibitors , 2013, Genes to cells : devoted to molecular & cellular mechanisms.
[16] D. Heymann,et al. Mechanisms of bone repair and regeneration. , 2009, Trends in molecular medicine.
[17] A. Petrilli,et al. C-kit expression in human osteosarcoma and in vitro assays. , 2011, International journal of clinical and experimental pathology.
[18] N. Sevenet,et al. Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity. , 2006, European journal of pharmacology.
[19] B. Pitard,et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. , 2007, Cancer research.
[20] D. Heymann,et al. Bone sarcomas: pathogenesis and new therapeutic approaches , 2011 .
[21] M. Heymann,et al. Current Therapeutic Strategies and Novel Approaches in Osteosarcoma , 2013, Cancers.
[22] S. Stacker,et al. Importance of Wnt signaling in the tumor stroma microenvironment. , 2008, Current cancer drug targets.
[23] X. Zi,et al. The Wnt signaling pathway: implications for therapy in osteosarcoma , 2011, Expert review of anticancer therapy.
[24] C. Supuran,et al. The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian alpha-carbonic anhydrase isoforms. , 2009, Bioorganic & medicinal chemistry letters.
[25] A. Freywald,et al. Dancing with the dead: Eph receptors and their kinase-null partners. , 2011, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[26] A. Fedenko,et al. A Meta-Analysis of Osteosarcoma Outcomes in the Modern Medical Era , 2012, Sarcoma.
[27] R. Gorlick,et al. Inhibition of Src Phosphorylation Alters Metastatic Potential of Osteosarcoma In vitro but not In vivo , 2009, Clinical Cancer Research.
[28] B. Klein,et al. Studies of bone and soft‐tissue tumours induced in rats with radioactive cerium chloride , 1977, International journal of cancer.
[29] P. Hogendoorn,et al. Concise Review: Mesenchymal Tumors: When Stem Cells Go Mad , 2011, Stem cells.
[30] G. Moriceau,et al. Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. , 2010, Cancer research.
[31] J. Cornish,et al. Imatinib Promotes Osteoblast Differentiation by Inhibiting PDGFR Signaling and Inhibits Osteoclastogenesis by Both Direct and Stromal Cell‐Dependent Mechanisms , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[32] O. Delattre,et al. Mesenchymal stem cell features of Ewing tumors. , 2007, Cancer cell.
[33] Jingnan Shen,et al. Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients. , 2013, Biochemical and biophysical research communications.
[34] G. Ehninger,et al. Inhibition of platelet‐derived growth factor receptorβ by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro , 2007, Cell proliferation.
[35] Francisco Cervantes,et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.
[36] K. Vandyke,et al. Dysregulation of bone remodeling by imatinib mesylate. , 2010, Blood.
[37] S R Piersma,et al. Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery , 2013, British Journal of Cancer.
[38] Raphaela Fritsche-Guenther,et al. De novo expression of EphA2 in osteosarcoma modulates activation of the mitogenic signalling pathway , 2010, Histopathology.
[39] G. Moriceau,et al. Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth , 2012, Cancer.
[40] J. Yokota,et al. Biological properties and gene expression associated with metastatic potential of human osteosarcoma , 2004, Clinical & Experimental Metastasis.
[41] K. Matsuo,et al. Bone cell interactions through Eph/ephrin , 2012, Cell adhesion & migration.
[42] P. Adamson,et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study , 2008, Pediatric blood & cancer.